These have been applied as mAbs in NIR-PIT; NIR-PIT with trastuzumab-IR700 showed valid results in a pleural dissemination model with HER2-expressing NSCLC cells and a lung metastasis model with HER2-expressing 3T3 cells [40,41,42]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.